BioAtla Investor Presentation Deck

Phase 1 CAB-CTLA-4 (BA3071): Confirmed Responses (n=2) and Stable Disease (n=9) Among 16 Evaluable Patients bicatla Change in Target Lesion from baseline (%) Data Cut Date: 15Nov23 100 80 60 40 20 O -20 -40 -60 -80 -100 0 5 10 15 Uveal melanoma 20 Gastro-esophageal (confirmed PR, 54.3% tumor reduction, post data cut) Cervical 25 30 Cutaneous melanoma 35 40 Time (Weeks) 45 BA3071 7mg Q3W + Nivo BA3071 21mg Q3W + Nivo BA3071 70mg Q3W + Nivo BA3071 210mg Q3W + Nivo BA3071 350mg Q3W + Nivo BA3071 700mg Q3W + Nivo Cutaneous melanoma 50 SCLC 55 60 65 70 BioAtla| Overview 17

View entire presentation